^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Tevimbra (tislelizumab-jsgr)

    i
    Other names: BGB-A317, BGB A317, VDT482, BGBA317, VDT 482, VDT-482
    Company:
    BeOne Medicines
    Drug class:
    PD1 inhibitor
    Related drugs:
    2d
    Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P1, N=69, Recruiting, Oncomatryx Biopharma S.L.
    New P1 trial
    |
    KRAS (KRAS proto-oncogene GTPase) • CA 19-9 (Cancer antigen 19-9)
    |
    gemcitabine • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • OMTX705
    3d
    Clinical trial of safety, tolerability and preliminary efficacy of crept-618 combined with tirelizumab injection in the treatment of unresectable hepatocellular carcinoma (ChiCTR2600117700)
    P=N/A, N=10, Not yet recruiting, People's Hospital of Deyang City; People's Hospital of Deyang City
    New trial
    |
    MUC4 (Mucin 4, Cell Surface Associated)
    |
    Tevimbra (tislelizumab-jsgr)
    3d
    TACE Combined with Tislelizumab and Lenvatinib in the Treatment of Unresectable Hepatocellular Carcinoma: A Randomized Controlled Clinical Study (ChiCTR2600117605)
    P=N/A, N=120, Not yet recruiting, West China Hospital, Sichuan University; West China Hospital, Sichuan University
    New trial
    |
    Lenvima (lenvatinib) • Tevimbra (tislelizumab-jsgr)
    3d
    A multicenter, prospective, observational cohort study comparing lenvatinib mesylate and tislelizumab in combination with RALOX-HAIC versus combination with FOLFOX-HAIC for the treatment of advanced hepatocellular carcinoma (ChiCTR2600117082)
    P=N/A, N=444, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University o
    New trial
    |
    5-fluorouracil • Lenvima (lenvatinib) • Tevimbra (tislelizumab-jsgr) • leucovorin calcium
    3d
    Efficacy and Safety Study of Oral Paclitaxel Solution Combined with Tislelizumab and Cetuximab as Neoadjuvant Therapy in Elderly Patients with Platinum-Intolerant Head and Neck Squamous Cell Carcinoma (ChiCTR2600116935)
    P=N/A, N=60, Not yet recruiting, Shanghai Ninth People's Hospital; Shanghai Ninth People's Hospital
    New trial
    |
    Erbitux (cetuximab) • paclitaxel • Tevimbra (tislelizumab-jsgr)
    3d
    Prospective Cohort Study on the Efficacy and Safety of Sequential TIPS-TACE/HAIC Combined or Not Combined with Donafenib and Tislelizumab in the Treatment of BCLC Stage C Hepatocellular Carcinoma Patients with Concomitant Portal Hypertension (ChiCTR2600116845)
    P=N/A, N=96, Not yet recruiting, Beijing Youan Hospital, Capital Medical University; Beijing Youan Hospital, Capital Medical University
    New trial
    |
    Tevimbra (tislelizumab-jsgr) • Zepsun (donafenib)
    3d
    Maintenance Therapy with Tislelizumab after Postoperative Chemotherapy in Upper Tract Urothelial Carcinoma (ChiCTR2500115259)
    P=N/A, N=54, Not yet recruiting, The First Affiliated Hospital of Wenzhou Medical University; The First Affiliated Hospital of Wenzhou Medical University
    New trial
    |
    Tevimbra (tislelizumab-jsgr)
    3d
    Tislelizumab Combined With Anlotinib and Nab-paclitaxel in III Resectable Non-small Cell Lung Cancer : A Prospective, Single-Arm, Phase II Study (ChiCTR2500114484)
    P=N/A, N=34, Not yet recruiting, Qilu Hospital of Shandong University; Qilu Hospital of Shandong University
    New trial
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    Focus V (anlotinib) • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel
    3d
    Investigate the impact of intratumoral neutrophils on gastric cancer patients undergoing neoadjuvant immunotherapy (ChiCTR2500112589)
    P=N/A, N=22, Not yet recruiting, West China Hospital, Sichuan University; West China Hospital, Sichuan University
    New trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tevimbra (tislelizumab-jsgr)
    3d
    A single-arm, multicenter, open-label clinical study to evaluate the efficacy and safety of trifluridine/tipiracil combined with tislelizumab and bevacizumab in patients with third-line or later locally advanced unresectable or metastatic colorectal cancer (ChiCTR2500112562)
    P=N/A, N=57, Recruiting, The Fourth Hospital of Hebei Medical University; The Fourth Hospital of Hebei Medical University
    New trial
    |
    Avastin (bevacizumab) • Tevimbra (tislelizumab-jsgr) • Lonsurf (trifluridine/tipiracil)
    3d
    Study on the Efficacy of Tislelizumab Combined With Lenvatinib and HAIC as Neoadjuvant Therapy Followed by Tislelizumab Adjuvant Therapy in Hepatocellular Carcinoma Patients With High Risk of Recurrence (ChiCTR2500112315)
    P=N/A, N=40, Not yet recruiting, The First Affiliated Hospital of Wenzhou Medical University; The First Affiliated Hospital of Wenzhou Medical University
    New trial
    |
    Lenvima (lenvatinib) • Tevimbra (tislelizumab-jsgr)
    3d
    Efficacy and Safety of Radiotherapy Combined With Tislelizumab and Anlotinib in the Treatment of Hepatocellular Carcinoma Complicated With Portal Vein Tumor Thrombus (ChiCTR2500112169)
    P=N/A, N=27, Not yet recruiting, Henan Cancer Hospital; Henan Cancer Hospital
    New trial
    |
    Focus V (anlotinib) • Tevimbra (tislelizumab-jsgr)